Recombinant human T2 RNase and uses thereof

US8039240B2 · kind B2 · utility

Assignee

• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL

Inventors

• Levava Roiz · Givat Shmuel, IL
• Betty Schwartz · Rehovot, IL
• Patricia Smirnoff · Rehovot, IL
• Oded Shoseyov · Karmei Yosef, IL

Key dates

• Filing date: Sep 28, 2005
• Grant date: Oct 18, 2011
• Expiry date: Jan 10, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The cloning and heterologous expression of human T2 RNase6PL are disclosed. Further disclosed are methods for preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The methods are effected by administering to the subject a therapeutically effective amount of a RNase6PL ribonuclease or close homologues thereof.